Pemvidutide (ALT-801)

Pemvidutide is an investigational synthetic peptide that activates both the GLP-1 and glucagon receptors, with a balance toward glucagon activity that distinguishes it from other co-agonists in the class.

Pemvidutide was developed by Altimmune as a balanced GLP-1 / glucagon dual receptor agonist, with the glucagon-receptor arm tuned to support hepatic lipid handling and energy expenditure alongside the GLP-1 appetite-suppressing arm. The development strategy emphasized MASH (metabolic dysfunction-associated steatohepatitis), where glucagon-driven hepatic lipid mobilization may be particularly relevant.

GLP-1 receptor activation contributes appetite suppression and glycemic control. The glucagon-receptor arm contributes increased energy expenditure and direct hepatic effects on lipid handling — particularly relevant to MASH where intrahepatic triglyceride content is a primary therapeutic target.

Designed for once-weekly subcutaneous dosing. Trial doses have explored multiple titration paths to balance efficacy with GI tolerability.

The peer-reviewed literature on Pemvidutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Phase 2/3 trial protocols use once-weekly subcutaneous administration with stepwise titration.

Pemvidutide is one of the more interesting MASH-focused incretin programs, and a useful illustration of how the dual-agonist concept is being tuned for indication-specific outcomes rather than maximum weight loss alone. It will be one to watch alongside survodutide, retatrutide, and the resmetirom-class non-incretin liver agents as the MASH treatment landscape develops.